SCHEMBL6409480

SCHEMBL6409480

NCc1ccccc1-c1ncccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.54
ADRB2 P07550 1/20 0.45
LOXL2 Q9Y4K0 1/20 0.44
CASP6 P55212 1/20 0.44
PNMT P11086 3/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
MAPT P10636 2/20 0.38
HRH1 P35367 1/20 0.38
ADORA2A P29274 1/20 0.36
ADRA1A P35348 2/20 0.36
NOS3 P29474 2/20 0.36
NOS1 P29475 2/20 0.36
NOS2 P35228 2/20 0.36
ATR Q13535 1/20 0.35
ADRA1D P25100 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29473237 1.00 DPP4 (0.54) DPP4ADRB2LOXL2CASP6PNMT
SCHEMBL17794539 0.82 DPP4 (0.58) DPP4LOXL2PNMTALDH1A1NOS3
Hydrochloric Acid SCHEMBL28773304 0.82 HRH1 (0.47) DPP4ADRB2CASP6CYP1A2CYP2D6
SCHEMBL3790206 0.79 KDM4E (0.50) DPP4LOXL2CYP1A2ALDH1A1KDM4E
SCHEMBL29496884 0.79 KDM4E (0.50) DPP4LOXL2CYP1A2ALDH1A1KDM4E
SCHEMBL23082861 0.78 CYP2D6 (0.44) CASP6CYP1A2CYP2D6ALDH1A1KDM4E
SCHEMBL28294207 0.78 CASP6 (0.47) DPP4CASP6CYP1A2CYP2D6ALDH1A1
SCHEMBL3787333 0.78 DPP4 (0.73) DPP4LOXL2PNMTNOS3NOS1
SCHEMBL28966789 0.77 CASP6 (0.42) DPP4CASP6CYP1A2CYP2D6ALDH1A1
SCHEMBL16814935 0.76 DPP4 (0.51) DPP4LOXL2PNMTNOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119395-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-04-21 US disclosed
CN-105461699-B Substituted heterocyclic compound and its application method and purposes 广东东阳光药业有限公司 2019-07-09 CN disclosed
CN-103467386-B Aryl pyrimidine ortho-position monocyano compounds and synthesis method thereof UNIV SHANGHAI 2015-05-27 CN disclosed
CN-103467386-A Aryl pyrimidine ortho-position monocyano compounds and synthesis method thereof UNIV SHANGHAI 2013-12-25 CN disclosed
CN-101585814-B Aryl pyrimidine ortho-single halogen substituted compound and synthetic method thereof UNIV SHANGHAI SCIENCE & TECH 2011-08-10 CN disclosed
CN-101585814-A Aryl pyrimidine ortho-single halogen substituted compound and synthetic method thereof UNIV SHANGHAI SCIENCE & TECH (CN) 2009-11-25 CN disclosed
US-20050171131-A1 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists KOSOGOF CHRISTI (US) 2005-08-04 US disclosed
US-20050070712-A1 Pyrimidine derivatives as ghrelin receptor modulators ABBOTT LABORATORIES 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119395-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 DPP4 651/4885ADRB2 480/4885LOXL2 3562/4885
US-20050171131-A1 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists GHSR, GIPR, GPR119 DPP4 127/4885ADRB2 1999/4885LOXL2 4172/4885
US-20050070712-A1 Pyrimidine derivatives as ghrelin receptor modulators GPR119, GIPR, GCGR DPP4 372/4885ADRB2 1047/4885LOXL2 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.